Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Trial Profile

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Peripheral arterial disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 21 Aug 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top